Regulus Therapeutics Inc. Quarterly Net Income (Loss) Attributable to Parent in USD from Q1 2011 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
Regulus Therapeutics Inc. quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from Q1 2011 to Q3 2024.
  • Regulus Therapeutics Inc. Net Income (Loss) Attributable to Parent for the quarter ending September 30, 2024 was -$14.1M, a 79.7% decline year-over-year.
  • Regulus Therapeutics Inc. Net Income (Loss) Attributable to Parent for the twelve months ending September 30, 2024 was -$41.6M, a 44.7% decline year-over-year.
  • Regulus Therapeutics Inc. annual Net Income (Loss) Attributable to Parent for 2023 was -$30M, a 6.05% decline from 2022.
  • Regulus Therapeutics Inc. annual Net Income (Loss) Attributable to Parent for 2022 was -$28.3M, a 1.85% decline from 2021.
  • Regulus Therapeutics Inc. annual Net Income (Loss) Attributable to Parent for 2021 was -$27.8M, a 76.8% decline from 2020.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 -$41.6M -$14.1M -$6.24M -79.7% Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-07
Q2 2024 -$35.4M -$11M -$4.02M -57.4% Apr 1, 2024 Jun 30, 2024 10-Q 2024-11-07
Q1 2024 -$31.4M -$8.47M -$1.33M -18.6% Jan 1, 2024 Mar 31, 2024 10-Q 2024-11-07
Q4 2023 -$30M -$8.06M -$1.27M -18.6% Oct 1, 2023 Dec 31, 2023 10-K 2024-03-21
Q3 2023 -$28.8M -$7.82M -$273K -3.62% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-07
Q2 2023 -$28.5M -$7.01M +$245K +3.38% Apr 1, 2023 Jun 30, 2023 10-Q 2024-11-07
Q1 2023 -$28.7M -$7.14M -$420K -6.25% Jan 1, 2023 Mar 31, 2023 10-Q 2024-11-07
Q4 2022 -$28.3M -$6.8M +$338K +4.74% Oct 1, 2022 Dec 31, 2022 10-K 2024-03-21
Q3 2022 -$28.7M -$7.55M +$1.08M +12.5% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-09
Q2 2022 -$29.7M -$7.26M -$1.22M -20.3% Apr 1, 2022 Jun 30, 2022 10-Q 2023-11-09
Q1 2022 -$28.5M -$6.72M -$706K -11.7% Jan 1, 2022 Mar 31, 2022 10-Q 2023-11-09
Q4 2021 -$27.8M -$7.13M -$5.81M -440% Oct 1, 2021 Dec 31, 2021 10-K 2023-03-23
Q3 2021 -$22M -$8.63M -$7.1M -466% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-14
Q2 2021 -$14.9M -$6.03M +$913K +13.1% Apr 1, 2021 Jun 30, 2021 10-Q 2022-11-14
Q1 2021 -$15.8M -$6.01M -$76K -1.28% Jan 1, 2021 Mar 31, 2021 10-Q 2022-11-14
Q4 2020 -$15.7M -$1.32M +$3.57M +73% Oct 1, 2020 Dec 31, 2020 10-K 2021-03-09
Q3 2020 -$19.3M -$1.52M +$3.9M +71.9% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-12
Q2 2020 -$23.2M -$6.95M -$1.93M -38.5% Apr 1, 2020 Jun 30, 2020 10-Q 2021-11-12
Q1 2020 -$21.3M -$5.94M -$2.68M -82.1% Jan 1, 2020 Mar 31, 2020 10-Q 2021-11-12
Q4 2019 -$18.6M -$4.89M +$3.67M +42.9% Oct 1, 2019 Dec 31, 2019 10-K 2021-03-09
Q3 2019 -$22.3M -$5.42M +$4.85M +47.2% Jul 1, 2019 Sep 30, 2019 10-K 2021-03-09
Q2 2019 -$27.1M -$5.02M +$8.83M +63.8% Apr 1, 2019 Jun 30, 2019 10-K 2021-03-09
Q1 2019 -$35.9M -$3.26M +$12.8M +79.7% Jan 1, 2019 Mar 31, 2019 10-K 2021-03-09
Q4 2018 -$48.7M -$8.56M +$5.89M +40.7% Oct 1, 2018 Dec 31, 2018 10-K 2020-03-12
Q3 2018 -$54.6M -$10.3M +$5.56M +35.1% Jul 1, 2018 Sep 30, 2018 10-K 2020-03-12
Q2 2018 -$60.1M -$13.8M +$7.76M +35.9% Apr 1, 2018 Jun 30, 2018 10-K 2020-03-12
Q1 2018 -$67.9M -$16M +$4M +20% Jan 1, 2018 Mar 31, 2018 10-K 2020-03-12
Q4 2017 -$71.9M -$14.4M +$5.57M +27.8% Oct 1, 2017 Dec 31, 2017 10-K 2019-03-18
Q3 2017 -$77.5M -$15.8M +$3.69M +18.9% Jul 1, 2017 Sep 30, 2017 10-K 2019-03-18
Q2 2017 -$81.2M -$21.6M -$518K -2.46% Apr 1, 2017 Jun 30, 2017 10-K 2019-03-18
Q1 2017 -$80.7M -$20M +$1.19M +5.59% Jan 1, 2017 Mar 31, 2017 10-K 2019-03-18
Q4 2016 -$81.8M -$20M -$12.8M -177% Oct 1, 2016 Dec 31, 2016 10-K 2018-03-08
Q3 2016 -$69M -$19.5M -$6.52M -50.1% Jul 1, 2016 Sep 30, 2016 10-K 2018-03-08
Q2 2016 -$62.5M -$21.1M -$55K -0.26% Apr 1, 2016 Jun 30, 2016 10-K 2018-03-08
Q1 2016 -$62.5M -$21.2M -$6.72M -46.4% Jan 1, 2016 Mar 31, 2016 10-K 2018-03-08
Q4 2015 -$55.7M -$7.23M +$14.9M +67.4% Oct 1, 2015 Dec 31, 2015 10-K 2017-03-03
Q3 2015 -$70.7M -$13M -$3.2M -32.7% Jul 1, 2015 Sep 30, 2015 10-K 2017-03-03
Q2 2015 -$67.5M -$21M -$9.06M -75.7% Apr 1, 2015 Jun 30, 2015 10-K 2017-03-03
Q1 2015 -$58.4M -$14.5M -$1.75M -13.7% Jan 1, 2015 Mar 31, 2015 10-K 2017-03-03
Q4 2014 -$56.7M -$22.2M -$20.2M -1050% Oct 1, 2014 Dec 31, 2014 10-K 2016-02-23
Q3 2014 -$36.4M -$9.8M -$7.63M -353% Jul 1, 2014 Sep 30, 2014 10-K 2016-02-23
Q2 2014 -$28.8M -$12M -$4.63M -62.9% Apr 1, 2014 Jun 30, 2014 10-K 2016-02-23
Q1 2014 -$24.2M -$12.7M -$5.51M -76.2% Jan 1, 2014 Mar 31, 2014 10-K 2016-02-23
Q4 2013 -$18.7M -$1.93M +$4.95M +72% Oct 1, 2013 Dec 31, 2013 10-K 2015-02-19
Q3 2013 -$23.6M -$2.16M +$3.52M +61.9% Jul 1, 2013 Sep 30, 2013 10-K 2015-02-19
Q2 2013 -$27.1M -$7.35M -$4.75M -183% Apr 1, 2013 Jun 30, 2013 10-K 2015-02-19
Q1 2013 -$22.4M -$7.23M -$4.98M -222% Jan 1, 2013 Mar 31, 2013 10-K 2015-02-19
Q4 2012 -$17.4M -$6.88M -$4.86M -241% Oct 1, 2012 Dec 31, 2012 10-K 2014-02-28
Q3 2012 -$12.5M -$5.69M -$4.64M -444% Jul 1, 2012 Sep 30, 2012 10-K 2014-02-28
Q2 2012 -$7.91M -$2.6M -$346K -15.4% Apr 1, 2012 Jun 30, 2012 10-K 2014-02-28
Q1 2012 -$7.56M -$2.25M +$41K +1.79% Jan 1, 2012 Mar 31, 2012 10-K 2014-02-28
Q4 2011 -$7.6M -$2.02M Oct 1, 2011 Dec 31, 2011 10-K 2013-02-19
Q3 2011 -$1.05M Jul 1, 2011 Sep 30, 2011 10-K 2013-02-19
Q2 2011 -$2.25M Apr 1, 2011 Jun 30, 2011 10-K 2013-02-19
Q1 2011 -$2.29M Jan 1, 2011 Mar 31, 2011 10-K 2013-02-19
* An asterisk sign (*) next to the value indicates that the value is likely invalid.